← All trials
NCT05484154
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2023
- Primary completion
- Jul 31, 2026
- Completion date
- Oct 31, 2026
- First posted
- Aug 2, 2022
- Last posted
- Aug 2, 2022
- Enrollment
- 1400
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ZZ Biotech, LLCLead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)Collaborator
- University of South CarolinaCollaborator
- University of Southern CaliforniaCollaborator
- University of Southern CaliforniaOverall official - principal investigator
- University of CincinnatiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.